1. Home
  2. WLK vs INCY Comparison

WLK vs INCY Comparison

Compare WLK & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westlake Corporation

WLK

Westlake Corporation

HOLD

Current Price

$93.57

Market Cap

14.7B

Sector

Industrials

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$97.78

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WLK
INCY
Founded
1986
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Commercial Physical & Biological Resarch
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.7B
17.0B
IPO Year
2004
1994

Fundamental Metrics

Financial Performance
Metric
WLK
INCY
Price
$93.57
$97.78
Analyst Decision
Buy
Buy
Analyst Count
15
21
Target Price
$106.87
$103.52
AVG Volume (30 Days)
1.0M
1.3M
Earning Date
05-05-2026
04-28-2026
Dividend Yield
1.90%
N/A
EPS Growth
N/A
4173.33
EPS
N/A
1.47
Revenue
$11,170,000,000.00
$3,394,635,000.00
Revenue This Year
$5.51
$10.44
Revenue Next Year
$3.74
$10.99
P/E Ratio
N/A
$66.98
Revenue Growth
N/A
13.67
52 Week Low
$56.33
$62.84
52 Week High
$124.23
$112.29

Technical Indicators

Market Signals
Indicator
WLK
INCY
Relative Strength Index (RSI) 31.65 52.03
Support Level $91.76 $93.17
Resistance Level $103.00 $102.07
Average True Range (ATR) 3.85 3.21
MACD -2.00 0.10
Stochastic Oscillator 4.53 50.73

Price Performance

Historical Comparison
WLK
INCY

About WLK Westlake Corporation

Westlake Corp is a vertically integrated international manufacturer and marketer of both housing and infrastructure products and performance and essential materials that are designed to enhance the lives of people every day. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and international compounds businesses.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: